Search
Schedule a Meeting

Green Manufacturing

More and more companies are recognising that there are ways to enhance human health whilst reducing the impact on – or even helping – the environment. Many of our large and smaller clients are committing to achieving Net Zero goals. Specifically, in our formulation and manufacturing space, there is a strong desire to reduce solvent use, to eliminate waste and inefficiencies, and the energy burden of pharmaceutical manufacturing.

This is encouraging news for the Crystec team. On average our modified supercritical fluid antisolvent mSAS® process uses 27% less solvent than micronisation, and 80% less solvent than spray drying. With on average a 95% yield, mSAS® is 40% more energy efficient than spray drying and 80% more efficient than micronisation, measured in kWh per g

  • Reduced Solvent Waste
  • High Product Yields
  • Energy Efficient
  • Green Technology
  • Reduced Production Time

Find Out More

Improving Dissolution

40% of marketed drugs and up to 90% of those in development exhibit poor solubility1. mSAS® provides different ways to address this challenge, including through increasing surface area, reducing agglomeration, new solid-state forms, co-crystals or stabilised amorphous forms of drug molecules.
  • More details

Optimised Inhaled Therapies

mSAS® enables the design of drug particles of precise size and shape, that aerosolise even in patients who may struggle to breathe. As well as treating lung disease, inhaled therapies can be designed to enter the bloodstream, providing opportunities for fast onset and an alternative to painful injections.
  • More details

Enhancing Stability

Chemical and physical stability is vital to ensure that therapeutics can be manufactured, stored, transported and administered to patients without a loss of efficacy or safety. mSAS® enables manufacture of highly pure, residue-free drug particles, capable of resisting moisture, and able to withstand higher temperatures.
  • More details

Simplified Formulations

Formulation is often a complex, multi-step process, adding considerable time and cost to development. The mSAS® process involves a single step, and enables design of particles which contain all the components required for a medicine to perform, reducing the need for downstream processing.
  • More details

Biomolecule Processing

Biotherapeutics such as peptides, proateins, antibodies and oligonucleotides are often delicate and easily damaged. mSAS® provides a gentle way to process biomolecules as free-flowing powders, retaining high levels of activity, reducing cold chain and enabling easier reconstitution.
  • More details

Natural Products

Natural products are often highly complex and conventional approaches to their extraction, purification and formulation can be inefficient and often result in a poor-quality product. mSAS® simplifies production of natural products, allowing fine tuning of the components of a medicine and improvements in quality and consistency.
  • More details

Green Manufacturing

Improvements in human health should not come at the cost to the planet, yet traditional approaches to medicines manufacturing carry a high environmental burden. mSAS® enables the production of medicines with lower waste, reduced emissions, using less solvent, and greatly improved energy efficiency.
  • More details

Intellectual Property

Innovation in medicines development often requires robust protection of intellectual property (IP). The mSAS® process provides numerous opportunities to enhance IP, whether through novel solid-state forms, improved formulations or new routes of delivery.
  • More details